ElevateBio, a biotechnology company, presented data at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held in 2026. The presentations highlighted the company's expanded gene editing platform and services, covering new modalities, artificial intelligence (AI)-driven discovery, and lipid nanoparticle (LNP) delivery systems.
The company's platform includes technologies for base editing, prime editing, and other gene editing approaches. ElevateBio's AI discovery tools are designed to optimize guide RNA design and predict editing outcomes. The LNP delivery system aims to improve the targeted delivery of gene editing components to specific cells.
Specific data presented at the meeting included preclinical results demonstrating the efficacy and specificity of the company's gene editing technologies in various disease models. ElevateBio also showcased its end-to-end services for partners, from discovery through manufacturing.
The ASGCT Annual Meeting is a key event for the gene and cell therapy field, where companies and researchers present the latest scientific advances. ElevateBio's presence at the meeting underscores its role in the gene editing space.
